cambogin, camboginol, garcinol
| Name | Garcinol | ||
| PubChem CID | 5281560 | ||
| Molecular Weight | 602.8g/mol | ||
| Synonyms |
cambogin, camboginol, garcinol |
||
| Formula | C₃₈H₅₀O₆ | ||
| SMILES | CC(=CCC1CC2(C(=O)C(=C(C3=CC(=C(C=C3)O)O)O)C(=O)C(C2=O)(C1(C)C)CC=C(C)C)CC(CC=C(C)C)C(=C)C)C | ||
| InChI | 1S/C38H50O6/c1-22(2)11-13-27(25(7)8)20-37-21-28(15-12-23(3)4)36(9,10)38(35(37)44,18-17-24(5)6)34(43)31(33(37)42)32(41)26-14-16-29(39)30(40)19-26/h11-12,14,16-17,19,27-28,39-41H,7,13,15,18,20-21H2,1-6,8-10H3/b32-31-/t27-,28+,37+,38-/m0/s1 | ||
| InChIKey | DTTONLKLWRTCAB-BZSUNBQASA-N | ||
| CAS Number | 78824-30-3 | ||
| ChEBI ID | CHEBI:5276 | ||
| Herb ID | HBIN027349 | ||
| Structure | 
|
Download
2D
MOL
3D
MOL
|
|
| Chineses Pinyin | HuiHuiDou | ||
| Use Part | Seed | ||
| Habitat | GanSu, QingHai, Shaanxi, ShanXi, HeBei | ||
| Flavor | Sweet | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Fabales
-->Family: Fabaceae
-->Genus: Cicer
-->Species: Cicer arietinum
|
||
| Chineses Pinyin | NingMengAnYe | ||
| Use Part | Leaf | ||
| Habitat | FuJian, TaiWan, GuangDong, HaiNan, GuangXi | ||
| Flavor | Pungent, Bitter | ||
| Meridian Tropism | Spleen, Stomach, Liver | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Myrtales
-->Family: Myrtaceae
-->Genus: Eucalyptus
-->Species: Eucalyptus citriodora
|
||
| Chineses Pinyin | YinDuTengHuang | ||
| Species |
>Kingdom: Viridiplantae
-->Phylum: Streptophyta
-->Class: Equisetopsida
-->Order: Malpighiales
-->Family: Clusiaceae
-->Genus: Garcinia
-->Species: Garcinia indica
|
||
| Pair Name | Garcinol, Paclitaxel | |||
| Partner Name | Paclitaxel | |||
| Disease Info | [ICD-11: 2C60] | Breast cancer | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in G2/M phase | |||
| Gene Regulation | Down-regulation | Expression | BCL2 | hsa596 |
| Down-regulation | Cleavage | CASP3 | hsa836 | |
| Down-regulation | Expression | CCNA2 | hsa890 | |
| Up-regulation | Expression | CCNB1 | hsa891 | |
| Down-regulation | Expression | CDC25A | hsa993 | |
| Up-regulation | Expression | CDH1 | hsa999 | |
| Down-regulation | Expression | CDK1 | hsa983 | |
| Down-regulation | Activity | MMP2 | hsa4313 | |
| Down-regulation | Activity | MMP9 | hsa4318 | |
| Down-regulation | Phosphorylation | NFKBIA | hsa4792 | |
| Down-regulation | Expression | PLA2G6 | hsa8398 | |
| Up-regulation | Expression | PTGS1 | hsa5742 | |
| Down-regulation | Expression | PTGS2 | hsa5743 | |
| Down-regulation | Phosphorylation | RELA | hsa5970 | |
| Down-regulation | Expression | SNAI1 | hsa6615 | |
| Down-regulation | Expression | TIMP1 | hsa7076 | |
| Down-regulation | Expression | TWIST1 | hsa7291 | |
| Down-regulation | Expression | VEGFA | hsa7422 | |
| Down-regulation | Expression | ZEB1 | hsa6935 | |
| In Vitro Model | 4T1 | Malignant neoplasms of the mouse mammary gland | Mus musculus (Mouse) | CVCL_0125 |
| In Vivo Model | Balb/c mice were injected with 4T1-Luc cells (5×10⁴ in 0.2 ml of PBS) into the 4th mammary fat pad as described pre_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x005f_x0002_viously. | |||
| Result | Garcinol sensitizes breast cancer cells to Taxol through the suppression of caspase-3/iPLA2 and NF-κB/Twist1 signaling pathways in a mouse 4T1 breast tumor model | |||
| Pair Name | Garcinol, Cisplatin | |||
| Partner Name | Cisplatin | |||
| Disease Info | [ICD-11: 2C73] | Ovarian cancer | Investigative | |
| Biological Phenomena | Induction-->Blockade of cell cycle in S phase | |||
| Gene Regulation | Down-regulation | Phosphorylation | AKT1 | hsa207 |
| Up-regulation | Cleavage | CASP3 | hsa836 | |
| Down-regulation | Expression | CDH13 | hsa1012 | |
| Up-regulation | Cleavage | PARP1 | hsa142 | |
| Down-regulation | Phosphorylation | PIK3CA | hsa5290 | |
| In Vitro Model | OVCAR-3 | High grade ovarian serous adenocarcinoma | Homo sapiens (Human) | CVCL_0465 |
| Result | Our data demonstrated that garcinol has the potential to be used as an anticancer agent and may synergize the effect of DDP. These actions are most likely through the regulation of the PI3K/AKT and NF-κB pathways. | |||
| No. | Title | Href |
|---|---|---|
| 1 | Garcinol sensitizes breast cancer cells to Taxol through the suppression of caspase-3/iPLA2 and NF-κB/Twist1 signaling pathways in a mouse 4T1 breast tumor model. Food Funct. 2017 Mar 22;8(3):1067-1079. doi: 10.1039/c6fo01588c. | Click |
| 2 | Garcinol Alone and in Combination With Cisplatin Affect Cellular Behavior and PI3K/AKT Protein Phosphorylation in Human Ovarian Cancer Cells. Dose Response. 2020 May 19;18(2):1559325820926732. doi: 10.1177/1559325820926732. | Click |
